Role of iron deficiency and overload in the pathogenesis of diabetes and diabetic complications

Current Medicinal Chemistry

Volumn 16, Issue 1, 2009, Pages 113-129

  Liu, Qiuju ^a,c,d   Sun, Liang ^b   Tan, Yi ^a   Wang, Guanjun ^c   Lin, Xu ^b,e   Cai, Lu ^a,c,e  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^d THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^e NONE   (China)

Author keywords

Anemia; Diabetes; Diabetic complications; Ferritin; Insulin resistance; Iron; Iron deficiency; Iron overload

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; FERRITIN; GLITAZONE DERIVATIVE; HEME OXYGENASE 1; HEMOGLOBIN A1C; HEMOPROTEIN; HFE PROTEIN; INSULIN; IRON; IRON CHELATING AGENT; NEF PROTEIN; PROTEIN NEF4; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RETINOL BINDING PROTEIN; UNCLASSIFIED DRUG;

ALBUMINURIA; ANEMIA; BLOOD DONOR; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIETARY INTAKE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; FENTON REACTION; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HORMONE ACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PREGNANCY DIABETES MELLITUS; PROTEIN INTERACTION; REVIEW; RISK BENEFIT ANALYSIS; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HOMEOSTASIS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD;

EID: 61949188604     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787002862     Document Type: Review

References (152)

1. Cai, L.; Kang, Y.J. Oxidative stress and diabetic cardiomyopathy: A brief review. Cardiovasc. Toxicol., 2001, 1, 181-93.
2. Chyun, D.A.; Young, L.H. Diabetes mellitus and cardiovascular disease. Nurs. Clin. North Am., 2006, 41, 681-95, viii-ix.
3. Wilson, J.G.; Lindquist, J.H.; Grambow, S.C.; Crook, E.D.; Maher, J.F. Potential role of increased iron stores in diabetes. Am. J. Med. Sci., 2003, 325, 332-9.
4. Kahn, S.E.; Hull, R.L.; Utzschneider, K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444, 840-6.
5. Dongiovanni, P.; Valenti, L.; Ludovica Fracanzani, A.; Gatti, S.; Cairo, G.; Fargion, S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am. J. Pathol., 2008, 172, 738-47.
6. Beutler, E.; Hoffbrand, A.V.; Cook, J.D. Iron deficiency and overload. Hematology. Am. Soc. Hematol. Educ. Program, 2003, 40-61.
7. Swaminathan, S.; Fonseca, V.A.; Alam, M.G.; Shah, S.V. The role of iron in diabetes and its complications. Diabetes Care, 2007, 30, 1926-33.
8. Rajpathak, S.N.; Crandall, J.P.; Wylie-Rosett, J.; Kabat, G.C.; Rohan, T.E.; Hu, F.B. The role of iron in type 2 diabetes in humans. Biochim. Biophys. Acta, 2008. [Epub ahead of print].
9. Eaton, J.W.; Qian, M. Molecular bases of cellular iron toxicity. Free Radic. Biol. Med., 2002, 32, 833-40.
10. Rouault, T.A. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol., 2006, 2, 406-14.
11. Zimmermann, M.B.; Hurrell, R.F. Nutritional iron deficiency. Lancet, 2007, 370, 511-20.
12. Farnaud, S.; Rapisarda, C.; Bui, T.; Drake, A.; Cammack, R.; Evans, R.W. Identification of an iron-hepcidin complex. Biochem. J., 2008, 413, 553-7.
13. De Domenico, I.; Ward, D.M.; Kaplan, J. Hepcidin regulation: Ironing out the details. J. Clin. Invest., 2007, 117, 1755-8
14. Oates, P.S. The role of hepcidin and ferroportin in iron absorption. Histol. Histopathol., 2007, 22, 791-804.
15. Shi, H.; Bencze, K.Z.; Stemmler, T.L.; Philpott, C.C. A cytosolic iron chaperone that delivers iron to ferritin. Science, 2008, 320, 1207-10.
16. Chen, S.; Khan, Z.A.; Karmazyn, M.; Chakrabarti, S. Role of endothelin-1, sodium hydrogen exchanger-1 and mitogen activated protein kinase (MAPK) activation in glucose-induced cardiomyocyte hypertrophy. Diabetes Metab. Res. Rev., 2007, 23, 356-67.
17. Wiley, S.E.; Paddock, M.L.; Abresch, E.C.; Gross, L.; van der Geer, P.; Nechushtai, R.; Murphy, A.N.; Jennings, P.A.; Dixon, J.E. The Outer Mitochondrial Membrane Protein mitoNEET Contains a Novel Redox-active 2Fe-2S Cluster. J. Biol. Chem., 2007, 282, 23745-9.
18. Bruick, R.K. Oxygen sensing in the hypoxic response pathway: Regulation of the hypoxia-inducible transcription factor. Genes Dev., 2003, 17, 2614-23.
19. Kikuchi, G.; Yoshida, T.; Noguchi, M. Heme oxygenase and heme degradation. Biochem. Biophys. Res. Commun., 2005, 338, 558-67.
20. Baranano, D.E.; Rao, M.; Ferris, C.D.; Snyder, S.H. Biliverdin reductase: A major physiologic cytoprotectant. Proc. Natl. Acad. Sci. USA, 2002, 99, 16093-8.
21. Cai, L.; Tsiapalis, G.; Cherian, M.G. Protective role of zinc-metallothionein on DNA damage in vitro by ferric nitrilotriacetate (Fe-NTA) and ferric salts. Chem. Biol. Interact., 1998, 115, 141-51.
22. Papanikolaou, G.; Pantopoulos, K. Iron metabolism and toxicity. Toxicol. Appl. Pharmacol., 2005, 202, 199-211.
23. Cai, L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic. Biol. Med., 2006, 41, 851-61.
24. Davis, R.E.; McCann, V.J.; Nicol, D.J. Influence of iron-deficiency anaemia on the glycosylated haemoglobin level in a patient with diabetes mellitus. Med. J. Aust., 1983, 1, 40-1.
25. Tarim, O.; Kucukerdogan, A.; Gunay, U.; Eralp, O.; Ercan, I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr. Int., 1999, 41, 357-62.
26. El-Agouza, I.; Abu Shahla, A.; Sirdah, M. The effect of iron deficiency anaemia on the levels of haemoglobin subtypes: Possible consequences for clinical diagnosis. Clin. Lab. Haematol., 2002, 24, 285-9.
27. Coban, E.; Ozdogan, M.; Timuragaoglu, A. Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol., 2004, 112, 126-8.
28. Hashimoto, K.; Noguchi, S.; Morimoto, Y.; Hamada, S.; Wasada, K.; Imai, S.; Murata, Y.; Kasayama, S.; Koga, M. HbA1C, but not serum glycated albumin, is elevated in late pregnancy due to iron deficiency. Diabetes Care, 2008, 31, 1945-8.
29. Sathiyapriya, V.; Bobby, Z.; Vinod Kumar, S.; Selvaraj, N.; Parthibane, V.; Gupta, S. Evidence for the role of lipid peroxides on glycation of hemoglobin and plasma proteins in non-diabetic asthma patients. Clin. Chim. Acta, 2006, 366, 299-303.
30. Sundaram, R.C.; Selvaraj, N.; Vijayan, G.; Bobby, Z.; Hamide, A.; Rattina Dasse, N. Increased plasma malondialdehyde and fructosamine in iron deficiency anemia: Effect of treatment. Biomed. Pharmacother., 2007, 61, 682-5.
31. Balamurugan, R.; Selvaraj, N.; Bobby, Z.; Sathiyapriya, V. Increased glycated hemoglobin level in non-diabetic nephrotic children is associated with oxidative stress. Indian J. Physiol. Pharmacol., 2007, 51, 153-9.
32. Fernandez-Real, J.M.; Lopez-Bermejo, A.; Ricart, W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin. Chem., 2005, 51, 1201-5.
33. Fernandez-Real, J.M.; Penarroja, G.; Castro, A.; Garcia-Bragado, F.; Hernandez-Aguado, I.; Ricart, W. Blood letting in high-ferritin type 2 diabetes: Effects on insulin sensitivity and beta-cell function. Diabetes., 2002, 51, 1000-4.
34. Jiang, R.; Ma, J.; Ascherio, A.; Stampfer, M.J.; Willett, W.C.; Hu, F.B. Dietary iron intake and blood donations in relation to risk of type 2 diabetes in men: A prospective cohort study. Am. J. Clin. Nutr., 2004, 79, 70-5.
35. Meyers, D.G.; Strickland, D.; Maloley, P.A.; Seburg, J.K.; Wilson, J.E.; McManus, B.F. Possible association of a reduction in cardiovascular events with blood donation. Heart, 1997, 78, 188-93.
36. Meyers, D.G.; Jensen, K.C.; Menitove, J.E. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion, 2002, 42, 1135-9.
37. Zheng, H.; Cable, R.; Spencer, B.; Votto, N.; Katz, S.D. Iron stores and vascular function in voluntary blood donors. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1577-83.
38. Zacharski, L.R.; Chow, B.K.; Howes, P.S.; Shamayeva, G.; Baron, J.A.; Dalman, R.L.; Malenka, D.J.; Ozaki, C.K.; Lavori, P.W. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: A randomized controlled trial. JAMA, 2007, 297, 603-10.
39. Zheng, H.; Patel, M.; Cable, R.; Young, L.; Katz, S.D. Insulin Sensitivity, Vascular Function, and Iron Stores in Voluntary Blood Donors. Diabetes Care, 2007, 30, 2685-93.
40. Engberink, M.F.; Geleijnse, J.M.; Durga, J.; Swinkels, D.W.; de Kort, W.L.; Schouten, E.G.; Verhoef, P. Blood donation, body iron status and carotid intima-media thickness. Atherosclerosis, 2008, 196, 856-62.
41. Newman, B.H.; Pichette, S.; Pichette, D.; Dzaka, E. Adverse effects in blood donors after whole-blood donation: A study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion, 2003, 43, 598-603.
42. Farrugia, A. Iron and blood donation- an under-recognised safety issue. Dev. Biol. (Basel), 2007, 127, 137-46.
43. Thomas, M.C. The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. Semin. Nephrol., 2006, 26, 275-82.
44. Thomas, M.C. Anemia in diabetes: Marker or mediator of microvascular disease? Nat. Clin. Pract. Nephrol., 2007, 3, 20-30.
45. Vlagopoulos, P.T.; Tighiouart, H.; Weiner, D.E.; Griffith, J.; Pettitt, D.; Salem, D.N.; Levey, A.S.; Sarnak, M.J. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: The impact of chronic kidney disease. J. Am. Soc. Nephrol., 2005, 16, 3403-10.
46. Shu, D.H.; Ransom, T.P.; O'Connell, C.M.; Cox, J.L.; Kaiser, S.M.; Gee, S.A.; Rowe, R.C.; Ur, E.; Imran, S.A. Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes. Cardiovasc. Diabetol., 2006, 5, 8.
47. Iseki, K.; Kohagura, K. Anemia as a risk factor for chronic kidney disease. Kidney. Int. Suppl., 2007, S4-9.
48. Sohn, I.S.; Jin, E.S.; Jang, S.T.; Cho, J.M.; Kim, C.J.; Bae, J.H.; Moon, J.Y.; Lee, S.H.; Kim, M.J. Bloodletting-induced cardiomyopathy: Reversible cardiac hypertrophy in severe chronic anemia from long-term bloodletting with cupping. Eur. J. Echocardiogr., 2007. 9, 585-6.
49. Ascic-Buturovic, B.; Heljic, B. Effects of hyperglycemia and iron deficiency on kidney and heart function in type 2 diabetes disease. Bosn. J. Basic. Med. Sci., 2006, 6, 78-81.
50. Ritz, E.; Laville, M.; Bilous, R.W.; O'Donoghue, D.; Scherhag, A.; Burger, U.; de Alvaro, F. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am. J. Kidney Dis., 2007, 49, 194-207.
51. Silverberg, D.S.; Wexler, D.; Iaina, A.; Schwartz, D. The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clin. Exp. Nephrol., 2008. [Epub ahead of print].
52. Fernandez-Real, J.M.; Ricart-Engel, W.; Arroyo, E.; Balanca, R.; Casamitjana-Abella, R.; Cabrero, D.; Fernandez-Castaner, M.; Soler, J. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care, 1998, 21, 62-8.
53. Kim, N.H.; Oh, J.H.; Choi, K.M.; Kim, Y.H.; Baik, S.H.; Choi, D.S.; Kim, S.J. Serum ferritin in healthy subjects and type 2 diabetic patients. Yonsei. Med. J., 2000, 41, 387-92.
54. Hua, N.W.; Stoohs, R.A.; Facchini, F.S. Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. Br. J. Nutr., 2001, 86, 515-9.
55. Jehn, M.; Clark, J.M.; Guallar, E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care, 2004, 27, 2422-8.
56. D'Souza, R.F.; Feakins, R.; Mears, L.; Sabin, C.A.; Foster, G.R. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. Aliment. Pharmacol. Ther., 2005, 21, 519-24.
57. Rajpathak, S.; Ma, J.; Manson, J.; Willett, W.C.; Hu, F.B. Iron intake and the risk of type 2 diabetes in women: A prospective cohort study. Diabetes Care, 2006, 29, 1370-6.
58. Wrede, C.E.; Buettner, R.; Bollheimer, L.C.; Scholmerich, J.; Palitzsch, K.D.; Hellerbrand, C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur. J. Endocrinol., 2006, 154, 333-40.
59. Forouhi, N.G.; Harding, A.H.; Allison, M.; Sandhu, M.S.; Welch, A.; Luben, R.; Bingham, S.; Khaw, K.T.; Wareham, N.J. Elevated serum ferritin levels predict new-onset type 2 diabetes: Results from the EPIC-Norfolk prospective study. Diabetologia, 2007, 50, 949-56.
60. Jehn, M.L.; Guallar, E.; Clark, J.M.; Couper, D.; Duncan, B.B.; Ballantyne, C.M.; Hoogeveen, R.C.; Harris, Z.L.; Pankow, J.S. A prospective study of plasma ferritin level and incident diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Epidemiol., 2007, 165, 1047-54.
61. Vari, I.S.; Balkau, B.; Kettaneh, A.; Andre, P.; Tichet, J.; Fumeron, F.; Caces, E.; Marre, M.; Grandchamp, B.; Ducimetiere, P. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care, 2007, 30, 1795-801.
62. Valenti, L.; Fracanzani, A.L.; Dongiovanni, P.; Bugianesi, E.; Marchesini, G.; Manzini, P.; Vanni, E.; Fargion, S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: Evidence from a case-control study. Am. J. Gastroenterol., 2007, 102, 1251-8
63. Schulze, M.B.; Manson, J.E.; Willett, W.C.; Hu, F.B. Processed meat intake and incidence of Type 2 diabetes in younger and middle-aged women. Diabetologia, 2003, 46, 1465-73.
64. Sheu, W.H.; Chen, Y.T.; Lee, W.J.; Wang, C.W.; Lin, L.Y. A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin. Endocrinol (Oxf)., 2003, 58, 380-5.
65. Acton, R.T.; Barton, J.C.; Passmore, L.V.; Adams, P.C.; Speechley, M.R.; Dawkins, F.W.; Sholinsky, P.; Reboussin, D.M.; McLaren, G.D.; Harris, E.L.; Bent, T.C.; Vogt, T.M.; Castro, O. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care, 2006, 29, 2084-9.
66. Shi, Z.; Hu, X.; Yuan, B.; Pan, X.; Meyer, H.E.; Holmboe-Ottesen, G. Association between serum ferritin, hemoglobin, iron intake, and diabetes in adults in Jiangsu, China. Diabetes Care, 2006, 29, 1878-83.
67. Luan de, C.; Li, H.; Li, S.J.; Zhao, Z.; Li, X.; Liu, Z.M. Body iron stores and dietary iron intake in relation to diabetes in adults in North China. Diabetes Care, 2008, 31, 285-6.
68. Villegas, R.; Shu, X.O.; Gao, Y.T.; Yang, G.; Cai, H.; Li, H.; Zheng, W. The association of meat intake and the risk of type 2 diabetes may be modified by body weight. Int. J. Med. Sci., 2006, 3, 152-9.
69. Pietrangelo, A. Hereditary hemochromatosis. Annu. Rev. Nutr., 2006, 26, 251-70.
70. O'Sullivan, E.P.; McDermott, J.H.; Murphy, M.S.; Sen, S.; Walsh, C.H. Declining prevalence of diabetes mellitus in hereditary haemochromatosis-The result of earlier diagnosis. Diabetes Res. Clin. Pract., 2008, 81, 316-20.
71. Angelopoulos, N.G.; Zervas, A.; Livadas, S.; Adamopoulos, I.; Giannopoulos, D.; Goula, A.; Tolis, G. Reduced insulin secretion in normoglycaemic patients with beta-thalassaemia major. Diabet. Med., 2006, 23, 1327-31.
72. Shirasuga, N.; Hayashi, K.; Awai, M. Pancreatic islets after repeated injection of Fe3+-NTA. An ultrastructural study of diabetic rats. Acta. Pathol. Jpn., 1989, 39, 159-68.
73. Ramey, G.; Faye, A.; Durel, B.; Viollet, B.; Vaulont, S. Iron overload in Hepc1(-/-) mice is not impairing glucose homeostasis. FEBS Lett., 2007, 581, 1053-7.
74. Zhang, C.; Schulze, M.B.; Solomon, C.G.; Hu, F.B. A prospective study of dietary patterns, meat intake and the risk of gestational diabetes mellitus. Diabetologia., 2006, 49, 2604-13.
75. Chen, L.; Lei, L.; Jin, T.; Nordberg, M.; Nordberg, G.F. Plasma metallothionein antibody, urinary cadmium, and renal dysfunction in a Chinese type 2 diabetic population. Diabetes Care, 2006, 29, 2682-7.
76. Afkhami-Ardekani, M.; Rashidi, M. Iron status in women with and without gestational diabetes mellitus. J. Diabetes Complications, 2008, [Epub ahead of print].
77. Lao, T.T.; Ho, L.F. Impact of iron deficiency anemia on prevalence of gestational diabetes mellitus. Diabetes Care, 2004, 27, 650-6.
78. King, H. Epidemiology of glucose intolerance and gestational diabetes in women of childbearing age. Diabetes Care, 1998, 21 (Suppl 2), B9-13.
79. Janghorbani, M.; Stenhouse, E.; Jones, R.B.; Millward, A. Gestational diabetes mellitus in Plymouth, U.K.: Prevalence, seasonal variation and associated factors. J. Reprod. Med., 2006, 51, 128-34.
80. Van Campenhout, A.; Van Campenhout, C.; Lagrou, A.R.; Moorkens, G.; De Block, C.; Manuel-y-Keenoy, B. Iron-binding antioxidant capacity is impaired in diabetes mellitus. Free Radic. Biol. Med., 2006, 40, 1749-55.
81. Finck, B.N.; Lehman, J.J.; Leone, T.C.; Welch, M.J.; Bennett, M.J.; Kovacs, A.; Han, X.; Gross, R.W.; Kozak, R.; Lopaschuk, G.D.; Kelly, D.P. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest., 2002, 109, 121-30.
82. de Mello, V.D.; Zelmanovitz, T.; Perassolo, M.S.; Azevedo, M.J.; Gross, J.L. Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria. Am. J. Clin. Nutr., 2006, 83, 1032-8.
83. Qi, L.; van Dam, R.M.; Rexrode, K.; Hu, F.B. Heme iron from diet as a risk factor for coronary heart disease in women with type 2 diabetes. Diabetes Care, 2007, 30, 101-6.
84. Gross, J.L.; Zelmanovitz, T.; Moulin, C.C.; De Mello, V.; Perassolo, M.; Leitao, C.; Hoefel, A.; Paggi, A.; Azevedo, M.J. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: A randomized crossover trial. Diabetes Care, 2002, 25, 645-51.
85. Stark, R.; Roden, M. ESCI Award 2006. Mitochondrial function and endocrine diseases. Eur. J. Clin. Invest., 2007, 37, 236-48.
86. Colca, J.R.; McDonald, W.G.; Waldon, D.J.; Leone, J.W.; Lull, J.M.; Bannow, C.A.; Lund, E.T.; Mathews, W.R. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab., 2004, 286, E252-60.
87. Wiley, S.E.; Murphy, A.N.; Ross, S.A.; van der Geer, P.; Dixon, J.E. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc. Natl. Acad. Sci. USA, 2007, 104, 5318-23.
88. Hunter, R.L.; Choi, D.Y.; Ross, S.A.; Bing, G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci. Lett., 2008, 432, 198-201.
89. Zhou, G.; Li, C.; Cai, L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am. J. Pathol., 2004, 165, 2033-43.
90. Cussimanio, B.L.; Booth, A.A.; Todd, P.; Hudson, B.G.; Khalifah, R.G. Unusual susceptibility of heme proteins to damage by glucose during non-enzymatic glycation. Biophys. Chem., 2003, 105, 743-55.
91. Kang, J.H. Oxidative damage of DNA by the reaction of amino acid with methylglyoxal in the presence of Fe(III). Int. J. Biol. Macromol., 2003, 33, 43-8.
92. Xiao, H.; Cai, G.; Liu, M. Fe2+-catalyzed non-enzymatic glycosylation alters collagen conformation during AGE-collagen formation in vitro. Arch. Biochem. Biophys., 2007, 468, 183-92.
93. Cai, L.; Li, W.; Wang, G.; Guo, L.; Jiang, Y.; Kang, Y.J. Hyperglycemia-induced apoptosis in mouse myocardium: Mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes, 2002, 51, 1938-48.
94. Singh, J.; Chonkar, A.; Bracken, N.; Adeghate, E.; Latt, Z.; Hussain, M. Effect of streptozotocin-induced type 1 diabetes mellitus on contraction, calcium transient, and cation contents in the isolated rat heart. Ann. N Y. Acad. Sci., 2006, 1084, 178-90
95. Li, C.; Cao, L.; Zeng, Q.; Liu, X.; Zhang, Y.; Dai, T.; Hu, D.; Huang, K.; Wang, Y.; Wang, X.; Li, D.; Chen, Z.; Zhang, J.; Li, Y.; Sharma, R. Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type2 receptor expression. Cardiovasc. Drugs Ther., 2005, 19, 105-12.
96. Yaras, N.; Bilginoglu, A.; Vassort, G.; Turan, B. Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H912-20.
97. Ishizaka, N.; Saito, K.; Furuta, K.; Matsuzaki, G.; Koike, K.; Noiri, E.; Nagai, R. Angiotensin II-induced regulation of the expression and localization of iron metabolism-related genes in the rat kidney. Hypertens Res., 2007, 30, 195-202.
98. Ishizaka, N.; Saito, K.; Mitani, H.; Yamazaki, I.; Sata, M.; Usui, S.; Mori, I.; Ohno, M.; Nagai, R. Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation, 2002, 106, 1840-6.
99. Saito, K.; Ishizaka, N.; Aizawa, T.; Sata, M.; Iso-o, N.; Noiri, E.; Mori, I.; Ohno, M.; Nagai, R. Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-beta1 in the heart. Am. J. Physiol. Heart. Circ. Physiol., 2005, 288, H1836-43.
100. Saito, K.; Ishizaka, N.; Aizawa, T.; Sata, M.; Iso, O.N.; Noiri, E.; Ohno, M.; Nagai, R. Role of aberrant iron homeostasis in the upregulation of transforming growth factor-beta1 in the kidney of angiotensin II-induced hypertensive rats. Hypertens Res., 2004, 27, 599-607.
101. Ishizaka, N.; Saito, K.; Mori, I.; Matsuzaki, G.; Ohno, M.; Nagai, R. Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2282-8
102. Cosso, L.; Maineri, E.P.; Traverso, N.; Rosatto, N.; Pronzato, M.A.; Cottalasso, D.; Marinari, U.M.; Odetti, P. Induction of heme oxygenase 1 in liver of spontaneously diabetic rats. Free Radic. Res., 2001, 34, 189-91.
103. Hayashi, K.; Haneda, M.; Koya, D.; Maeda, S.; Isshiki, K.; Kikkawa, R. Enhancement of glomerular heme oxygenase-1 expression in diabetic rats. Diabetes Res. Clin. Pract., 2001, 52, 85-96.
104. Song, J.; Sumiyoshi, S.; Nakashima, Y.; Doi, Y.; Iida, M.; Kiyohara, Y.; Sueishi, K. Overexpression of heme oxygenase-1 in coronary atherosclerosis of Japanese autopsies with diabetes mellitus: Hisayama study. Atherosclerosis, 2008, [Epub ahead of print].
105. Paredi, P.; Biernacki, W.; Invernizzi, G.; Kharitonov, S.A.; Barnes, P.J. Exhaled carbon monoxide levels elevated in diabetes and correlated with glucose concentration in blood: A new test for monitoring the disease? Chest, 1999, 116, 1007-11.
106. Bruce, C.R.; Carey, A.L.; Hawley, J.A.; Febbraio, M.A. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: Evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism. Diabetes, 2003, 52, 2338-45.
107. Adaikalakoteswari, A.; Balasubramanyam, M.; Rema, M.; Mohan, V. Differential gene expression of NADPH oxidase (p22phox) and hemoxygenase-1 in patients with Type 2 diabetes and microangiopathy. Diabet. Med., 2006, 23, 666-74.
108. Goodman, A.I.; Chander, P.N.; Rezzani, R.; Schwartzman, M.L.; Regan, R.F.; Rodella, L.; Turkseven, S.; Lianos, E.A.; Dennery, P.A.; Abraham, N.G. Heme oxygenase-2 deficiency contributes to diabetes-mediated increase in superoxide anion and renal dysfunction. J. Am. Soc. Nephrol., 2006, 17, 1073-81.
109. Ma, M.M.; Chen, J.L.; Wang, G.G.; Wang, H.; Lu, Y.; Li, J.F.; Yi, J.; Yuan, Y.J.; Zhang, Q.W.; Mi, J.; Wang, L.S.; Duan, H.F.; Wu, C.T. Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia, 2007, 50, 891-900.
110. Kruger, A.L.; Peterson, S.J.; Schwartzman, M.L.; Fusco, H.; McClung, J.A.; Weiss, M.; Shenouda, S.; Goodman, A.I.; Goligorsky, M.S.; Kappas, A.; Abraham, N.G. Up-regulation of heme oxygenase provides vascular protection in an animal model of diabetes through its antioxidant and antiapoptotic effects. J. Pharmacol. Exp. Ther., 2006, 319, 1144-52.
111. Li, M.; Kim, D.H.; Tsenovoy, P.L.; Peterson, S.J.; Rezzani, R.; Rodella, L.F.; Aronow, W.S.; Ikehara, S.; Abraham, N.G. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes, 2008, 57, 1526-35.
112. Liu, X.; Wei, J.; Peng, D.H.; Layne, M.D.; Yet, S.F. Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice. Diabetes, 2005, 54, 778-84.
113. Merzouk, S.; Hichami, A.; Sari, A.; Madani, S.; Merzouk, H.; Yahia Berrouiguet, A.; Lenoir-Rousseaux, J.J.; Chabane-Sari, N.; Khan, N.A. Impaired oxidant/antioxidant status and LDL-fatty acid composition are associated with increased susceptibility to peroxidation of LDL in diabetic patients. Gen. Physiol. Biophys., 2004, 23, 387-99.
114. Duzguner, V.; Kaya, S. Effect of zinc on the lipid peroxidation and the antioxidant defense systems of the alloxan-induced diabetic rabbits. Free Radic. Biol. Med., 2007, 42, 1481-6.
115. Peerapatdit, T.; Patchanans, N.; Likidlilid, A.; Poldee, S.; Sriratanasathavorn, C. Plasma lipid peroxidation and antioxidiant nutrients in type 2 diabetic patients. J. Med. Assoc. Thai., 2006, 89 (Suppl 5), S147-55.
116. Farhangkhoee, H.; Khan, Z.A.; Mukherjee, S.; Cukiernik, M.; Barbin, Y.P.; Karmazyn, M.; Chakrabarti, S. Heme oxygenase in diabetes-induced oxidative stress in the heart. J. Mol. Cell Cardiol., 2003, 35, 1439-48.
117. Chen, S.; Khan, Z.A.; Barbin, Y.; Chakrabarti, S. Pro-oxidant role of heme oxygenase in mediating glucose-induced endothelial cell damage. Free Radic. Res., 2004, 38, 1301-10.
118. Wang, J.; Dore, S. Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage. Brain, 2007, 130, 1643-52.
119. Quadro, L.; Blaner, W.S.; Salchow, D.J.; Vogel, S.; Piantedosi, R.; Gouras, P.; Freeman, S.; Cosma, M.P.; Colantuoni, V.; Gottesman, M.E. Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. EMBO J., 1999, 18, 4633-44.
120. Yang, Q.; Graham, T.E.; Mody, N.; Preitner, F.; Peroni, O.D.; Zabolotny, J.M.; Kotani, K.; Quadro, L.; Kahn, B.B. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 2005, 436, 356-62.
121. Kovacs, P.; Geyer, M.; Berndt, J.; Kloting, N.; Graham, T.E.; Bottcher, Y.; Enigk, B.; Tonjes, A.; Schleinitz, D.; Schon, M.R.; Kahn, B.B.; Bluher, M.; Stumvoll, M. Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot-specific mRNA expression. Diabetes, 2007, 56, 3095-100.
122. Kowalska, I.; Straczkowski, M.; Adamska, A.; Nikolajuk, A.; Karczewska-Kupczewska, M.; Otziomek, E.; Gorska, M. Serum retinol binding protein 4 is related to insulin resistance and nonoxidative glucose metabolism in lean and obese women with normal glucose tolerance. J. Clin. Endocrinol. Metab., 2008, 93, 2786-9.
123. van Hoek, M.; Dehghan, A.; Zillikens, M.C.; Hofman, A.; Witteman, J.C.; Sijbrands, E.J. An RBP4 promoter polymorphism increases risk of type 2 diabetes. Diabetologia, 2008, 51, 1423-8.
124. Cabre, A.; Lazaro, I.; Girona, J.; Manzanares, J.; Marimon, F.; Plana, N.; Heras, M.; Masana, L. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J. Intern. Med., 2007, 262, 496-503.
125. Mejia, L.A.; Chew, F. Hematological effect of supplementing anemic children with vitamin A alone and in combination with iron. Am. J. Clin. Nutr., 1988, 48, 595-600.
126. Roodenburg, A.J.; West, C.E.; Hovenier, R.; Beynen, A.C. Supplemental vitamin A enhances the recovery from iron deficiency in rats with chronic vitamin A deficiency. Br. J. Nutr., 1996, 75, 623-36.
127. Fernandez-Real, J.M.; Moreno, J.M.; Ricart, W. Circulating retinol-binding protein-4 concentration might reflect insulin resistance-associated iron overload. Diabetes, 2008, 57, 1918-25.
128. Hattori, N.; Rihl, J.; Bengel, F.M.; Nekolla, S.G.; Standl, E.; Schwaiger, M.; Schnell, O. Cardiac autonomic dysinnervation and myocardial blood flow in long-term Type 1 diabetic patients. Diabet. Med., 2003, 20, 375-81.
129. Hattori, N.; Schnell, O.; Bengel, F.M.; Rihl, J.; Nekolla, S.G.; Drzezga, A.E.; Standl, E.; Schwaiger, M. Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 891-8.
130. Young, I.S.; Tate, S.; Lightbody, J.H.; McMaster, D.; Trimble, E.R. The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat. Free Radic. Biol. Med., 1995, 18, 833-40.
131. Roza, A.M.; Slakey, D.P.; Pieper, G.M.; Van Ye, T.M.; Moore-Hilton, G.; Komorowski, R.A.; Johnson, C.P.; Hedlund, B.E.; Adams, M.B. Hydroxyethyl starch deferoxamine, a novel iron chelator, delays diabetes in BB rats. J. Lab. Clin. Med., 1994, 123, 556-60.
132. Cameron, N.E.; Cotter, M.A. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J. Clin. Invest., 1995, 96, 1159-63.
133. Pieper, G.M.; Siebeneich, W. Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine. J. Cardiovasc. Pharmacol., 1997, 30, 734-8.
134. Cameron, N.E.; Cotter, M.A. Effects of an extracellular metal chelator on neurovascular function in diabetic rats. Diabetologia, 2001, 44, 621-8.
135. El-Khatib, A.S.; Moustafa, A.M.; Abdel-Aziz, A.A.; Al-Shabanah, O.A.; El-Kashef, H.A. Effects of aminoguanidine and desferrioxamine on some vascular and biochemical changes associated with streptozotocin-induced hyperglycaemia in rats. Pharmacol. Res., 2001, 43, 233-40.
136. Lai, T.Y.; Lee, G.K.; Chan, W.M.; Lam, D.S. Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion. Br. J. Ophthalmol., 2006, 90, 243-4.
137. Kontoghiorghes, G.J.; Nasseri-Sina, P.; Goddard, J.G.; Barr, J.M.; Nortey, P.; Sheppard, L.N. Safety of oral iron chelator L1. Lancet, 1989, 2, 457-8.
138. Kontoghiorghes, G.J. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin, 2006, 30, 329-47.
139. Kontoghiorghes, G.J.; Eracleous, E.; Economides, C.; Kolnagou, A. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr. Med. Chem., 2005, 12, 2663-81.
140. Platis, O.; Anagnostopoulos, G.; Farmaki, K.; Posantzis, M.; Gotsis, E.; Tolis, G. Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy. Pediatr. Endocrinol. Rev., 2004, 2 (Suppl 2), 279-81.
141. Christoforidis, A.; Perifanis, V.; Athanassiou-Metaxa, M. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major. Br. J. Haematol., 2006, 135, 271-2.
142. Christoforidis, A.; Perifanis, V.; Tsatra, I.; Vlachaki, E.; Athanassiou-Metaxa, M. Evolution of OGTT in patients with betathalassaemia major in relation to chelation therapy. Diabetes Res. Clin. Pract., 2007, 76, 6-11.
143. Farmaki, K.; Angelopoulos, N.; Anagnostopoulos, G.; Gotsis, E.; Rombopoulos, G.; Tolis, G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br. J. Haematol., 2006, 134, 438-44.
144. Thomas, G.N.; Chan, P.; Tomlinson, B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging, 2006, 23, 131-55.
145. Ritz, E. Anemia and diabetic nephropathy. Curr. Diab. Rep., 2006, 6, 469-72.
146. al-Refaie, F.N.; Wonke, B.; Wickens, D.G.; Aydinok, Y.; Fielding, A.; Hoffbrand, A.V. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. J. Clin. Pathol., 1994, 47, 657-60.
147. Lucas, G.N.; Perera, B.J.; Fonseka, E.A.; De Silva, D.D.; Fernandopulle, M.; Karunatilaka, D.H.; Weerasinghe, I. Experience with the oral iron chelator deferiprone in transfusion-dependent children. Ceylon. Med. J., 2002, 47, 119-21.
148. Al-Maroof, R.A.; Al-Sharbatti, S.S. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. Saudi. Med. J., 2006, 27, 344-50.
149. Soinio, M.; Marniemi, J.; Laakso, M.; Pyorala, K.; Lehto, S.; Ronnemaa, T. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes. Care, 2007, 30, 523-8
150. Olivares, M.; Pizarro, F.; Ruz, M. New insights about iron bioavailability inhibition by zinc. Nutrition., 2007, 23, 292-5.
151. Faure, P. Protective effects of antioxidant micronutrients (vitamin E, zinc and selenium) in type 2 diabetes mellitus. Clin. Chem. Lab. Med., 2003, 41, 995-8.
152. Umbreit, J. Iron deficiency: A concise review. Am. J. Hematol., 2005, 78, 225-31.